Rock Weekly – NEW

  • Expert analysis and proprietary data (e.g., longitudinal funding data, consumer adoption) 100% 100%
  • Insightful takes from the Rock Health Advisory team 100% 100%
  • Spotlight on startups, deals, partnerships, and emerging trends 100% 100%

    Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

    Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

    Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

    Your content goes here. Edit or remove this text inline or in the module Content settings. You can also style every aspect of this content in the module Design settings and even apply custom CSS to this text in the module Advanced settings.

    Name Goes Here

    Dr. R2D2

    How robots could change healthcare a bot

    Now you’re speaking my language

    Healthcare shouldn’t get lost in translation

    Q1 2022 funding recap: $6B raised across 183 deals

    Staying the course in choppy waters

    Can “addiction tech” curb an escalating crisis?

    Addressing the opioid epidemic.

    The new tech galaxies in the healthcare space

    How will today’s maturing technologies redefine the healthcare space?

    The who, what, when, and why of wearables

    Survey shows trends in ownership and usage.

    The doctor is in…your home speaker

    Care in the home comes to your Amazon Alexa.

    Putting a pin in exit plans

    Private funds favorable in an uncertain exit environment.

    What’s next for DTx?

    VR, R&D, + GTM—oh my!

    Impact examined

    Fallout from the Dobbs’ ruling, one year later.